Drug Profile

AR Variant Degrader - Novartis

Alternative Names: AR-V7 degrader - Arvinas

Latest Information Update: 14 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Yale University
Developer Arvinas
Class Antineoplastics; Small molecules
Mechanism of Action Androgen receptor degradation enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Prostate cancer

Most Recent Events

28 May 2024 Novartis acquires AR Variant Degrader from Arvinas
20 Oct 2022 Preclinical trials in Prostate cancer in USA (unspecified route) (Arvinas pipeline; October 2022)
01 Feb 2021 Arvinas co-owned patents for PROTAC targeted protein degraders in USA ((3571013)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com